Welcome to our dedicated page for Clarivate news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate stock.
Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Clarivate Plc (NYSE: CLVT) has launched a resource center to support displaced researchers from Ukraine. This initiative includes over 200 ProQuest Books available freely, a program ensuring continued access to the Web of Science for Ukrainian institutions, and the RapidILL interlibrary loan system for academic resources. This follows Clarivate's decision to cease commercial activities in Russia. The resource center aims to enhance knowledge and understanding of Ukraine while providing critical support for research and discovery.
Clarivate Plc (NYSE: CLVT) has released a report titled Walking the talk on patient centricity, highlighting the importance of personalized patient engagement in life sciences. The report identifies four pillars essential for achieving patient centricity: data inputs, patient involvement, a customer experience approach, and a real-world mindset. It stresses the urgency for life science companies to adapt to this trend for better drug and service outcomes, particularly post-COVID-19. Understanding patient needs is crucial for driving value for both patients and investors.
Clarivate Plc (NYSE: CLVT) released its Biopharma Deals in Review report, showcasing the significant trends in biopharma deal-making for 2021. The report highlights a record 1,968 deals valued at $213.6 billion, with substantial investments in RNA, gene therapies, AI, and oncology. US biotech companies led global capital raising, accounting for 67% of all funds. Notably, oncology deals represented 29% of transactions, with several exceeding $1 billion. This analysis emphasizes the evolving landscape and the growing interest in innovative therapies.
Clarivate Plc (NYSE: CLVT), a global leader in innovation insights, announced its participation in the Bank of America 2022 Information Services Conference. Jerre Stead, Executive Chair and CEO, along with CFO Jonathan Collins, will present on March 17, 2022, at 8:55 AM Eastern Time. A live webcast of the presentation will be accessible via the company's Investor Relations page, with a replay available for 30 days post-event. Clarivate is committed to accelerating innovation and solving complex problems in science and intellectual property.
Clarivate reported strong financial results for Q4 and full year 2021, with revenues of $560.7 million for Q4 (up 23.1%) and $1.88 billion for the year (up 49.7%). Adjusted Net Income soared 20.4% in Q4, reaching $163.2 million, while for the year, it hit $481.7 million, a 66.6% increase. Subscription revenues rose 25.4% in Q4, driven by the ProQuest acquisition. However, the company faced a net loss of $130.4 million in Q4, reflecting a significant increase from the prior year, primarily due to higher interest expenses and warrant adjustments.
Clarivate Plc (NYSE: CLVT) announced it will release its financial results for Q4 and the full year 2021 on March 10, 2022, prior to market opening. The earnings supplement will be available on its investor website at ir.clarivate.com. A conference call and webcast will be held on the same day at 9:00 AM Eastern Time to discuss the results. Investors can join the live audio broadcast by calling specific numbers for the US, Canada, and international participants. A replay will be accessible until March 23, 2022.
Summary not available.
BioWorld, published by Clarivate Plc (NYSE:CLVT), released an in-depth analysis on long COVID-19, affecting over 100 million globally. The report analyzes 40+ studies assessing the syndrome, developed a consensus definition for standardized research, and tracks 41 drugs in development. Despite the biotech industry's focus on COVID-19 treatments, effective therapeutics for long COVID remain scarce, with only three in late-stage trials. The social impact could be significant as researchers continue to explore disease timelines and symptoms across diverse demographics.
Clarivate Plc (NYSE:CLVT) has opened applications for the Eugene Garfield Award™, recognizing early-career scientists in citation analysis. The award, with a $25,000 unrestricted prize, aims to promote diversity and inclusion by encouraging submissions from emerging nations, especially in Africa and Asia. Established in 2017, it honors Dr. Eugene Garfield's legacy in bibliometrics. Applications are due by July 1, 2022, with the winner announced on September 1, 2022. The award seeks innovative approaches to scientific evaluation using citation data.
On February 7, 2022, Clarivate Plc (NYSE: CLVT; CLVT.PR.A) announced a $1.0 billion share repurchase program approved by its Board of Directors, set to execute through December 31, 2023. This program replaces a previous one from August 2021. Additionally, the Board declared a quarterly dividend of $1.3125 per share on its Series A Mandatory Convertible Preferred Shares, payable on March 1, 2022. Jerre Stead, CEO, emphasized the company's strong cash flow and belief in the current share price as a compelling investment opportunity.